Table 1. Evaluation of STAT3 mutations incidence in T-LGL leukemia patients according to clinical characteristics.
| Variable | T-LGL leukemia patients n = 101 | Patients with STAT3 mutation n = 38 | Patients without STAT3 mutation n = 63 | P | STAT3 mutations |
|---|---|---|---|---|---|
| Gender | 0.048 | ||||
| Males | 50 (50%) | 14 (37%) | 36 (57%) | 8 Y640F, 2 D661Y, 1 D661V, 1 N647I, 1 G656_Y657insY, 1 K658R and I659_M660insL | |
| Females | 51 (50%) | 24 (63%) | 27 (43%) | 16 Y640F, 7 D661Y, 1 A662_N663delinsH | |
| Neutropenia (ANC < 1,500) | 39 (39%) | 34 (89%) | 5 (8%) | 0.0001 | 21 Y640F, 8 D661Y, 1 D661V, 1 N647I, 1 G656_Y657insY, 1 K658R and I659_M660insL, 1 A662_N663delinsH |
| Severe neutropenia (ANC < 500) | 17 (17%) | 17 (45%) | 0 | 0.0001 | 10 Y640F, 4 D661Y, 1 N647I, 1 K658R and I659_M660insL, 1 A662_N663delinsH |
| Rheumatoid arthritis | 3 (3%) | 3 (8%) | 0 | 0.024 | 2 Y640F, 1 D661Y |
| Other autoimmune diseases | 23 (23%) | 16 (42%) | 7 (11%) | 0.0001 | 11 Y640F, 4 D661Y, 1 K658R and I659_M660insL |
| Associated neoplasia | 28 (28%) | 8 (21%) | 20 (32%) | 0.245 | 5 Y640F, 2 D661Y, 1 K658R and I659_M660insL |
| Treatment | 13 (13%) | 12 (32%) | 1 (2%) | 0.0001 | 8 Y640F, 3 D661Y, 1 G656_Y657insY |
ANC, absolute neutrophil count.